Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 238,413 |
|
|||||
| News | - | ||||||
| Day High | 2.82 | Low High |
|||||
| Day Low | 2.55 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genelux Corporation | GNLX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.24 | -8.54% | 2.57 | 16:25:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.82 | 2.55 | 2.82 | 2.57 | 2.81 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,490 | 238,413 | $ 2.65 | $ 631,732 | - | 2.50 - 40.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:20:00 | 1 | $ 2.55 | USD |
Genelux Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 68.4M | 26.72M | - | 170k | -28.3M | -1.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Genelux News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNLX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.69 | 2.86 | 2.55 | 2.77 | 412,840 | -0.12 | -4.46% |
| 1 Month | 3.89 | 5.75 | 2.50 | 3.22 | 411,426 | -1.32 | -33.93% |
| 3 Months | 7.09 | 7.15 | 2.50 | 3.72 | 218,844 | -4.52 | -63.75% |
| 6 Months | 13.82 | 16.60 | 2.50 | 6.37 | 169,419 | -11.25 | -81.40% |
| 1 Year | 28.71 | 40.98 | 2.50 | 14.00 | 163,207 | -26.14 | -91.05% |
| 3 Years | 6.00 | 40.98 | 2.50 | 15.08 | 146,146 | -3.43 | -57.17% |
| 5 Years | 6.00 | 40.98 | 2.50 | 15.08 | 146,146 | -3.43 | -57.17% |
Genelux Description
| Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. |
